6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1h)-pyrimidinone profile

6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone: inhibits the Mrer11-Rad50-Nbs1 complex; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2898799
MeSH ID	M0518211

Synonym
BB 0222349
6-(4-hydroxy-phenyl)-2-thioxo-2,3-dihydro-1 h-pyrimidin-4-one
SDCCGMLS-0065098.P001
6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1h)-pyrimidinone
AG-690/40721842
OPREA1_281197
OPREA1_346353
AKOS001650664
6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1h)-one
STK066272
AKOS005485814
6-(4-hydroxyphenyl)-2-sulfanylidene-1h-pyrimidin-4-one
STK560354
6-(4-hydroxyphenyl)-2-sulfanylpyrimidin-4-ol
375834-47-2
sr-01000470560
SR-01000470560-1
mfcd02241157
6-(4-hydroxyphenyl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one
CCG-344504
SB59191
LS-03818
CS-0320191
6-(4-hydroxyphenyl)-2-mercaptopyrimidin-4-ol

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (15.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (20.00)	29.6817
2010's	11 (55.00)	24.3611
2020's	2 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.15	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.08	1	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
ku 55933 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source	2.11	1
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	3.25	1	organic heterotricyclic compound; organooxygen compound
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	3.25	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
veliparib [no description available]	3.25	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
mk-8776 MK-8776: a checkpoint kinase 1 (CHK1) inhibitor; SCH900776 was renamed MK-8776; structure in first source	2.07	1	pyrazolopyrimidine
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	5.41	19

Condition	Relationship Strength	Studies
Cancer of Ovary [description not available]	2.6	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.6	1
Genome Instability [description not available]	2.17	1
Benign Neoplasms [description not available]	3.48	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.48	2
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.17	1
Abnormalities, Autosome [description not available]	2.11	1
Osteogenic Sarcoma [description not available]	2.07	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.07	1
Ataxia Telangiectasia Syndrome [description not available]	2.04	1
Ataxia Telangiectasia An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23).	2.04	1

6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1h)-pyrimidinone

Description

Cross-References

Synonyms (24)

Research

Studies (20)

Market Indicators

Research Demand Index: 11.50

Study Types